Products Categories
CAS No.: | 144598-75-4 |
---|---|
Name: | Paliperidone |
Article Data: | 57 |
Molecular Structure: | |
Formula: | C23H27FN4O3 |
Molecular Weight: | 426.491 |
Synonyms: | 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4- (6-fluoro-1,2-benzisoxazol-3-yl)-1- piperidinyl]ethyl]-6,7,8,9-tetrahydro-9- hydroxy-2-methyl-;9-Hydroxyrisperidone; |
EINECS: | 620-493-1 |
Density: | 1.45 g/cm3 |
Melting Point: | 158-160 °C |
Boiling Point: | 612.3 °C at 760 mmHg |
Flash Point: | 324.1 °C |
Appearance: | off white to light orange coloured solid |
Hazard Symbols: | T |
Risk Codes: | 25 |
Safety: | 45 |
Transport Information: | UN 2811 6.1/PG 3 |
PSA: | 84.39000 |
LogP: | 3.01920 |
Product Name: Paliperidone (CAS NO.144598-75-4)
Molecular Formula: C23H27FN4O3
Molecular Weight: 426.48g/mol
Mol File: 144598-75-4.mol
Appearance: Off White to Light Orange Coloured Solid
Melting Point: 158-160°C
Boiling point: 612.32 °C at 760 mmHg
Storage Temperature: Room temp
Flash Point: 324.12 °C
Density: 1.45 g/cm3
Surface Tension: 54.583 dyne/cm
Enthalpy of Vaporization: 95.571 kJ/mol
XLogP3-AA: 2.2
H-Bond Donor: 1
H-Bond Acceptor: 7
Structure Descriptors of Paliperidone (CAS NO.144598-75-4):
IUPAC Name: (9R)-3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
Canonical SMILES: CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
Isomeric SMILES: CC1=C(C(=O)N2CCC[C@H](C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
InChI: InChI=1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3/t19-/m1/s1
InChIKey: PMXMIIMHBWHSKN-LJQANCHMSA-N
Product Categories: Various Metabolites and Impurities; Intermediates & Fine Chemicals; Metabolites & Impurities; Pharmaceuticals
Paliperidone is an atypical antipsychotic developed by Janssen Pharmaceutica. Invega is an extended release formulation of paliperidone that uses the OROS extended release system to allow for once-daily dosing. Paliperidone (as Invega) was approved by the FDA for the treatment of schizophrenia on December 20, 2006.
It is indicated for the acute and maintenance treatment of schizophrenia. The drug significantly reduces side-effects present in other anti-psychotic drugs formerly used to treat schizophrenia and bipolar disorder. In short-term studies paliperidone has been shown to be effective, demonstrating improvements in symptom scores, compared with placebo.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
rat | LD50 | oral | 65mg/kg (65mg/kg) | Drug Development Research. Vol. 33, Pg. 399, 1994. |
Safety Information of Paliperidone (CAS NO.144598-75-4):
Hazard Codes: T
Risk Statements: 25
R25 :Toxic if swallowed.
Safety Statements: 45
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
RIDADR: UN 2811 6.1/PG 3
RTECS: UV1164720
Paliperidone , its CAS NO. is 144598-75-4, the synonyms are (9RS)-3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidin-1-
yl))ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido(1,2-a)pyrimidin-4-one ; 4H-Pyrido(1,2-a)pyrimidin-4-one, 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl- ; 9-Hydroxyrisperidone ; Invega ; Paliperidone ; RO76477 ; UNII-838F01T721 .